HeartBeam, Inc. BEAT

Company Overview

HeartBeam, Inc. is a medical technology company focused on cardiac monitoring and cardiac diagnostic solutions. The company develops electrocardiogram (ECG) technologies intended to improve the detection and monitoring of heart disease outside of traditional clinical settings. HeartBeam operates within the digital health, remote patient monitoring, and cardiovascular diagnostics industries, with an emphasis on portable and ambulatory cardiac assessment tools. Its primary revenue and strategic focus have centered on the development and commercialization of proprietary ECG hardware, software, and cloud-based analytics designed to capture heart signals from multiple directions and provide physicians with data comparable to traditional in-office cardiac testing.

The company’s core technology platform is designed around a credit card–sized ECG device capable of collecting three-dimensional cardiac electrical signals. HeartBeam positions its technology as an alternative to conventional single-lead wearable monitors by seeking to provide higher-fidelity cardiac data for arrhythmia and ischemia evaluation. The company evolved from an early-stage cardiac technology developer into a publicly traded digital health company through a merger transaction involving a special purpose acquisition company in 2021. Since then, HeartBeam has focused on regulatory advancement, software integration, physician connectivity, and commercialization planning within the broader remote cardiovascular care market.

Business Operations

HeartBeam primarily operates through a unified cardiac technology business focused on ambulatory ECG monitoring and cardiac data analytics. The company’s principal assets include proprietary ECG signal acquisition technology, cloud-connected software infrastructure, and artificial intelligence-enabled analytical tools intended to support clinicians in evaluating cardiac conditions remotely. Revenue generation has historically been limited as the company remains in a development and pre-commercial scaling phase, with operations largely supported through capital raises, public market financing, and strategic development activities disclosed in SEC filings.

The company’s operations are centered in the United States, where it conducts product development, regulatory activities, clinical validation, and commercialization planning. HeartBeam has developed partnerships with healthcare technology providers and clinical organizations to support validation studies, physician workflow integration, and future distribution capabilities. The company has also highlighted software-driven cardiac assessment capabilities and intellectual property related to vector-based ECG signal processing as part of its competitive positioning in remote cardiac diagnostics.

Strategic Position & Investments

HeartBeam’s strategic direction focuses on expanding access to remote cardiac diagnostics through compact hardware, software analytics, and telehealth-enabled physician connectivity. The company has prioritized U.S. regulatory pathways for its ECG technologies and has invested in artificial intelligence and digital infrastructure intended to support scalable cardiovascular monitoring. Growth initiatives have included clinical studies, FDA-related development activities, and integration efforts aimed at improving physician interpretation and patient usability.

The company has also pursued strategic collaborations and technology investments intended to strengthen its diagnostic ecosystem. HeartBeam has emphasized intellectual property development, including patents related to 3D ECG signal capture and synthesis. Public disclosures indicate ongoing investment in software capabilities, cloud infrastructure, and machine-learning applications for cardiac analysis. While the company remains comparatively small relative to established cardiac device manufacturers, it seeks differentiation through portable form factors and multi-directional ECG data acquisition intended to approximate more comprehensive clinical cardiac assessments outside traditional healthcare settings.

Geographic Footprint

HeartBeam is headquartered in Santa Clara, California, and its operational activities are primarily concentrated in the United States. The company’s development, regulatory, and commercialization initiatives have largely targeted the U.S. healthcare market, particularly providers and patients involved in remote cardiovascular monitoring and ambulatory care.

Although HeartBeam does not currently maintain the same international operational scale as major multinational medical device firms, its technology strategy addresses broader global trends in telemedicine, remote diagnostics, and decentralized healthcare delivery. The company’s intellectual property and digital-health orientation provide potential applicability across international healthcare systems, though publicly available disclosures indicate that commercial operations remain primarily U.S.-focused at this stage.

Leadership & Governance

HeartBeam’s leadership team includes executives with backgrounds in medical devices, digital health, cardiovascular technology, and healthcare commercialization. Governance oversight is provided through its board of directors and executive management team, with strategic emphasis placed on regulatory execution, clinical validation, and market expansion in remote cardiac diagnostics.

Key executives include:

• Robert Eno – Chief Executive Officer
• Timothy Cruickshank – Chief Financial Officer
• Branislav Vajdic, Ph.D. – Founder and Chief Technology Officer
• Deborah Hallgren – Senior Vice President of Clinical and Regulatory Affairs

The company’s leadership philosophy has emphasized expanding access to cardiac care through portable diagnostics and data-driven monitoring solutions. Management communications in public filings and investor materials consistently focus on innovation in ambulatory ECG technology, physician-enabled remote diagnostics, and the broader transition toward decentralized healthcare delivery.